177 related articles for article (PubMed ID: 31500577)
21. Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.
Eckstein M; Jung R; Weigelt K; Sikic D; Stöhr R; Geppert C; Agaimy A; Lieb V; Hartmann A; Wullich B; Wach S; Taubert H
Sci Rep; 2018 Dec; 8(1):17693. PubMed ID: 30523270
[TBL] [Abstract][Full Text] [Related]
22. Oncological Outcomes in Patients Treated with Radical Cystectomy for Bladder Cancer: Comparison Between Open, Laparoscopic, and Robot-Assisted Approaches.
Kim TH; Sung HH; Jeon HG; Seo SI; Jeon SS; Lee HM; Choi HY; Jeong BC
J Endourol; 2016 Jul; 30(7):783-91. PubMed ID: 27055782
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.
Elwy AE; Elsaba TM; Abd Elzaher AR; Nassar MI
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3735-3746. PubMed ID: 31870116
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.
Ikeda J; Ohe C; Yoshida T; Kuroda N; Saito R; Kinoshita H; Tsuta K; Matsuda T
Pathol Int; 2021 Mar; 71(3):173-182. PubMed ID: 33503295
[TBL] [Abstract][Full Text] [Related]
26. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
27. SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.
Keck B; Wach S; Goebell PJ; Kunath F; Bertz S; Lehmann J; Stöckle M; Taubert H; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Oct; 20(11):3669-74. PubMed ID: 23807662
[TBL] [Abstract][Full Text] [Related]
28. Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
Muilwijk T; Akand M; Van der Aa F; De Coninck V; Claessens M; Hente R; Eckstein M; Allory Y; Libbrecht L; Joniau S; Gevaert T
J Cell Mol Med; 2021 Aug; 25(16):7890-7900. PubMed ID: 34184816
[TBL] [Abstract][Full Text] [Related]
29. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
30. Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping.
Gürbüz BÇ; Topal CS; Sobay R; Alkurt G; Zemheri IE
Pathol Res Pract; 2021 Jan; 217():153308. PubMed ID: 33341088
[TBL] [Abstract][Full Text] [Related]
31. Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
Kim JM; Choi E; Sung SH; Kang H; Park S
Pathol Res Pract; 2023 Nov; 251():154839. PubMed ID: 37801908
[TBL] [Abstract][Full Text] [Related]
32. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
Kriegmair MC; Balk M; Wirtz R; Steidler A; Weis CA; Breyer J; Hartmann A; Bolenz C; Erben P
Anticancer Res; 2016 Oct; 36(10):5205-5213. PubMed ID: 27798881
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer.
Chen Y; Cui T; Yang L; Mireskandari M; Knoesel T; Zhang Q; Pacyna-Gengelbach M; Petersen I
Oncology; 2011; 80(5-6):333-40. PubMed ID: 21791943
[TBL] [Abstract][Full Text] [Related]
34. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
36. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
37. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
[TBL] [Abstract][Full Text] [Related]
38. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy.
Morizawa Y; Miyake M; Shimada K; Hori S; Tatsumi Y; Nakai Y; Anai S; Tanaka N; Konishi N; Fujimoto K
Urol Oncol; 2016 Jun; 34(6):257.e11-7. PubMed ID: 27038696
[TBL] [Abstract][Full Text] [Related]
40. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]